Medicare to Pay for Image Guidance in Biopsy of Palpable Breast Lesions

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

WASHINGTON-Medicare will soon cover image guidance techniques, such as stereotactic systems and ultrasound, used to biopsy palpable breast lesions that are difficult to biopsy with palpitation alone. However, contractors who administer Medicare benefits "have the discretion to decide what types of palpable lesions are difficult to biopsy using palpitation," the Centers for Medicare and Medicaid Services said. The new coverage will begin later this year and will not be retroactive. Medicare has covered image guidance to assist the biopsy of nonpalpable lesions since 1999.

WASHINGTON—Medicare will soon cover image guidance techniques, such as stereotactic systems and ultrasound, used to biopsy palpable breast lesions that are difficult to biopsy with palpitation alone. However, contractors who administer Medicare benefits "have the discretion to decide what types of palpable lesions are difficult to biopsy using palpitation," the Centers for Medicare and Medicaid Services said. The new coverage will begin later this year and will not be retroactive. Medicare has covered image guidance to assist the biopsy of nonpalpable lesions since 1999.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content